BriaCell Therapeutics Corp. Quarterly Nonoperating Income (Expense) in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
BriaCell Therapeutics Corp. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2021 to Q3 2024.
  • BriaCell Therapeutics Corp. Nonoperating Income (Expense) for the quarter ending October 31, 2024 was $11.7K, a 93.5% decline year-over-year.
  • BriaCell Therapeutics Corp. Nonoperating Income (Expense) for the twelve months ending October 31, 2024 was $94.5K.
  • BriaCell Therapeutics Corp. annual Nonoperating Income (Expense) for 2024 was $263K, a 69.1% decline from 2023.
  • BriaCell Therapeutics Corp. annual Nonoperating Income (Expense) for 2023 was $850K.
  • BriaCell Therapeutics Corp. annual Nonoperating Income (Expense) for 2022 was -$11.5M, a 68.9% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $94.5K $11.7K -$168K -93.5% Aug 1, 2024 Oct 31, 2024 10-Q 2024-12-16
Q2 2024 $263K -$9.39M -$12.6M -396% May 1, 2024 Jul 31, 2024 10-K 2024-10-29
Q1 2024 $12.8M $11M +$10.2M +1302% Feb 1, 2024 Apr 30, 2024 10-Q 2024-06-14
Q4 2023 $2.64M -$1.49M +$5.91M +79.9% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-18
Q3 2023 -$3.27M $180K -$4.12M -95.8% Aug 1, 2023 Oct 31, 2023 10-Q 2024-12-16
Q2 2023 $850K $3.17M -$1.62M -33.8% May 1, 2023 Jul 31, 2023 10-K 2024-10-29
Q1 2023 $2.47M $782K +$6.67M Feb 1, 2023 Apr 30, 2023 10-Q 2024-06-14
Q4 2022 -$4.21M -$7.4M -$22.2M -150% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-18
Q3 2022 $18M $4.3M +$29.5M Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-14
Q2 2022 -$11.5M $4.78M May 1, 2022 Jul 31, 2022 10-K 2023-10-25
Q1 2022 -$5.89M Feb 1, 2022 Apr 30, 2022 10-Q 2023-06-14
Q4 2021 $14.8M Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-16
Q3 2021 -$25.2M Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.